Brought to you by 
Chiasma partners acromegaly candidate Octreolin with Roche; terminated
08 Apr 2020
Executive Summary
Israeli biotech Chiasma Inc. has licensed Roche exclusive global rights to its lead orphan drug candidate, Phase III Octreolin (octreotide). The first indication for the peptide therapeutic will be acromegaly (a growth disorder caused by the pituitary gland producing excessive growth hormone in the body), and a second potential use may be in neuroendocrine tumors, which are also related to the increased presence of growth hormone.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chiasma partners acromegaly candidate Octreolin with Roche; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice